---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-052220"
form_type: "8-K"
ticker: "VSTM"
cik: "0001526119"
company_name: "Verastem, Inc."
filed_at: "2025-05-23T23:59:59+00:00"
generated_at: "2026-05-20T14:04:19.896231+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Verastem reports 83% ORR for avutometinib+defactinib in front-line metastatic PDAC

## Summary
- Dose level 1 (RP2D) achieved 83% ORR (10/12 partial responses) in RAMP 205 trial of frontline metastatic pancreatic cancer.
- Across all 5 dose cohorts, 92% (48/52) of evaluable patients showed tumor reduction.
- Company plans to start registrational Phase 3 trial in front-line metastatic PDAC in 2026.
- No new safety signals; adverse events consistent with previously reported profile.
- R&D webcast on June 2, 2025 to discuss RAMP 205 data and VS-7375 KRAS G12D inhibitor data.

## SEC filing metadata
- accession: 0001104659-25-052220
- form_type: 8-K
- ticker: VSTM
- cik: 0001526119
- company_name: Verastem, Inc.
- filed_at: 2025-05-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.07, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1526119/000110465925052220/0001104659-25-052220-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1526119/000110465925052220/tm2516049d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-052220
- JSON: https://secwatch.observer/filing/0001104659-25-052220.json
- Plain text: https://secwatch.observer/filing/0001104659-25-052220.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.